UBS (Lux) EF Glb Sust (USD) I-A2-acc

Performance (in USD)

Past performance is no indication of current or future performance. These performance data do not take account of the commissions and costs incurred on the issue and redemption of units.

Performance

1 month -4.67%
Current year -4.01%
3 years p.a. 6.77%
5 years p.a. 12.91%
10 years p.a. n.a.
Since inception p.a. n.a.

Rolling performance in %

Key figures

YTD 1 year 3 years 5 years 10 years
Performance -4.01% 2.03% 21.73% 83.60% n.a.
Maximum profit on monthly basis 4.48% 4.48% 8.57% 14.15% n.a.
Maximum loss on monthly basis -5.07% -5.07% -9.41% -9.41% n.a.
Max drawdown -17.74% -17.74% -17.74% -28.10% n.a.
Volatility 22.74% 16.51% 16.42% 16.20% n.a.
Sharpe ratio -0.65 -0.01 0.25 0.71 n.a.
Maximum continuous profit in months 1 5 5 7 n.a.
Maximum continuous loss in months 2 2 3 3 n.a.
Positive months / profit duration in months 2 8 23 39 n.a.
Negative months / loss duration in months 2 5 14 22 n.a.

Master data

Fund name UBS (Lux) EF Glb Sust (USD) I-A2-acc
Fund management company UBS Asset Management (Europe) S.A.
Fund domicile Luxembourg
Inception date 21 August 2019
ISIN LU2035667513
Swiss security no. 49194338
Fund currency USD
Appropriation of income accumulating
Issuing commission
Ongoing charges under PRIIP KID as at 14 July 2021 0.70%
End of financial year 30 November
Paying agent
Fund volume as at 30 November 2021 868.83 Mio. USD
Net asset value (NAV) as at 23 April 2025 170.40 USD

Portfolio structure

Top holdings of fund volume (in %)

Microsoft 4.33%
Amazon.com 3.34%
Akamai Tech. 2.49%
Sony 2.47%
Linde PLC Reg.Shares 2.21%
Cadence Design Sys. 2.14%
Unitedhealth Group 2.09%
Delphi Autom. Syst. 2.00%
Ingersoll Rand 1.96%
Bio Rad Labs 1.86%

Asset allocation

Currency

Countries

Sectors